Coagulation factor VII–tissue factor complex (FVII–TF complex)

The **coagulation factor VII–tissue factor complex** is a membrane-bound enzymatic complex central to the initiation of the coagulation cascade via the extrinsic pathway. **Factor VIIa** is a trypsin-like serine protease circulating mostly as a zymogen (VII) and is weakly active alone. Upon vascular injury, the extracellular domain of **tissue factor** (a transmembrane receptor/cofactor protein) is exposed to blood and rapidly binds circulating factor VIIa. Complex formation allosterically activates factor VIIa, enhancing its protease activity by several orders of magnitude[3][1][2]. The complex proteolytically activates coagulation factors IX and X to their respective active enzymes (IXa and Xa), ultimately leading to thrombin generation and fibrin clot formation. Both the integrity of cell membranes (for optimal complex formation) and the presence of divalent cations (e.g., Ca²⁺, Mg²⁺) are critical for physiological activity. Besides coagulation, the complex is implicated in cellular signaling in cancer and inflammation. Pharmacologically, it is targeted to either enhance hemostasis (e.g., in hemophilia) or inhibit thrombosis, but both deficiencies and over-activation lead to significant clinical consequences[4][3][2][1].

Other names

Factor VII–tissue factor complexVIIa–TF complexFactor VIIa–tissue factorExtrinsic tenase complex

Promotion of coagulation by activating factor IX and X via proteolytic cleavage. Inhibition of coagulation by blocking the TF–factor VIIa interaction or inhibiting its active site. Recombinant FVIIa therapy restores hemostatic activity in bleeding disorders.